Abstract:The development of the most successful cancer immunotherapies in solid tumors, immune-checkpoint blockade, has focused on factors regulating T-cell activation. Until recently, the field has maintained a predominately T-cell centric view of immunotherapy, leaving aside the impact of innate immunity and especially myeloid cells. Dendritic cells (DC) are dominant partners of T cells, necessary for initiation of adaptive immune responses. Emerging evidence supports a broader role for DCs in tumors including the maintenance and support of effector functions during T-cell responses. This relationship is evidenced by the association of activated DCs with immune-checkpoint blockade responses and transcriptional analysis of responding tumors demonstrating the presence of type I IFN transcripts and DC relevant chemokines. T-cell-inflamed tumors preferentially respond to immunotherapies compared with non–T-cell-inflamed tumors and this model suggests a potentially modifiable spectrum of tumor microenvironmental immunity. Although host and commensal factors may limit the T-cell-inflamed phenotype, tumor cell intrinsic factors are gaining prominence as therapeutic targets. For example, tumor WNT/β-catenin signaling inhibits production of chemokine gradients and blocking DC recruitment to tumors. Conversely, mechanisms of innate immune nucleic acid sensing, normally operative during pathogen response, may enhance DC accumulation and make tumors more susceptible to cancer immunotherapy. Elucidating mechanisms whereby DCs infiltrate and become activated within tumors may provide new opportunities for therapeutic intervention. Conceptually, this would facilitate conversion of non–T-cell-inflamed to T-cell-inflamed states or overcome secondary resistance mechanisms in T-cell-inflamed tumors, expanding the proportion of patients who benefit from cancer immunotherapy.

Dendritic cells as orchestrators of anticancer immunity and immunotherapy

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Dendritic cell subsets and implications for cancer immunotherapy

The role of dendritic cells in cancer immunity and therapeutic strategies

Dendritic Cells in Cancer Immunology and Immunotherapy

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

Dendritic cell biology and its role in tumor immunotherapy

Dendritic cells: the yin and yang in disease progression

Exploring dendritic cell subtypes in cancer immunotherapy: unraveling the role of mature regulatory dendritic cells

Dendritic cell subsets in cancer immunity and tumor antigen sensing

Current state of knowledge and challenges for harnessing the power of dendritic cells in cancer immunotherapy

Dendritic Cells in Shaping Anti-Tumor T Cell Response

Impaired function of dendritic cells within the tumor microenvironment

Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

Chapter Three - Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer

Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance

BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients

Dysfunction of dendritic cells in tumor microenvironment and immunotherapy

Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells

Effector Functions of Dendritic Cells in Cancer: Role of Cytotoxicity and Growth Inhibition

Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response